Building durable RNA therapeutics for regenerative medicine.
Durable protein expression from a low-dose RNA platform
Reduced treatment burden for patients and caregivers
Scalable manufacturing, avoiding expensive biologic production
Platform approach across multiple therapeutic proteins and indications
Translation-focused development, designed for partnering and scale
Our belief
Ending the burden of age-related disease requires changing how medicines are delivered.
Today’s biologic therapies are often effective, but they require repeated dosing, complex manufacturing, and high cost. We believe durable treatment can be achieved using temporary RNA instructions—without permanent genetic change.
Our technology
We develop self-amplifying RNA (saRNA) therapeutics engineered for sustained therapeutic effect.
Instead of manufacturing therapeutic proteins outside the body, we deliver a temporary RNA instruction that enables a patient’s own cells to produce the medicine. Because the RNA is self-amplifying, a small dose can drive therapeutic protein production over a longer period of time.
The RNA provides the recipe, works for a defined period, and then naturally degrades.
Where we start
We are advancing programs in age-related skeletal disease, where durability and delivery efficiency can meaningfully change patient care.
Our lead focus is bone health, including osteoporosis and impaired regeneration, where long-lasting therapeutic protein expression could reduce dosing burden and improve accessibility.
Why this platform matters
Aging is the leading driver of global healthcare burden. Conditions such as osteoporosis, frailty, and impaired tissue repair affect millions and contribute to disability, hospitalization, and rising healthcare costs.
RNARevive is building a platform designed to deliver durable therapeutic protein expression, enabling a scalable pipeline of RNA-encoded biologics across multiple tissues and indications.